Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7550984,detection limit,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),[ng] / [ml],2,6147,DB00842,Oxazepam
,7550984,signal-to-noise ratio,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),,3,6148,DB00842,Oxazepam
>,7550984,Recoveries,Recoveries of the analytes and the internal standard (prazepam) were > 82%.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,82,6149,DB00842,Oxazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,3.9,6150,DB00842,Oxazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,6.6,6151,DB00842,Oxazepam
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,2.8,6152,DB00842,Oxazepam
,2737234,Total oxazepam clearance,Total oxazepam clearance was 1.04 ml.min-1.kg-1 and it decreased 0.88-fold after the diet.,Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737234/),[ml] / [kg·min],1.04,9944,DB00842,Oxazepam
,2737234,elimination half-life,"The elimination half-life increased to 1.22-times the control value, 7.9 h.",Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737234/),h,7.9,9945,DB00842,Oxazepam
,2737234,clearance,"Antipyrine clearance, estimated by the one-sample technique, was 52.4 and 51.8 ml.",Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737234/),ml,52.4,9946,DB00842,Oxazepam
,2737234,clearance,"Antipyrine clearance, estimated by the one-sample technique, was 52.4 and 51.8 ml.",Influence of a very low calorie diet on the clearance of oxazepam and antipyrine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737234/),ml,51.8,9947,DB00842,Oxazepam
,6127197,time to peak,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,2.99,10627,DB00842,Oxazepam
,6127197,elimination half-life,Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours.,"Temazepam (Restoril, Sandoz Pharmaceuticals). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127197/),h,14.7,10628,DB00842,Oxazepam
,3930095,limit of detection,The limit of detection in serum is about 10 micrograms/L for each drug.,"Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),[μg] / [l],10,15853,DB00842,Oxazepam
,3930095,Analytical recovery,"Analytical recovery of each drug added to the serum varied from 91 to 102% for oxazepam and temazepam, from 82 to 99% for nordiazepam and diazepam.","Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),%,91 to 102,15854,DB00842,Oxazepam
,3930095,Analytical recovery,"Analytical recovery of each drug added to the serum varied from 91 to 102% for oxazepam and temazepam, from 82 to 99% for nordiazepam and diazepam.","Liquid-chromatographic assay of diazepam and its major metabolites in serum, and application to pharmacokinetic study of high doses of diazepam in schizophrenics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3930095/),%,82 to 99,15855,DB00842,Oxazepam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,29,19159,DB00842,Oxazepam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,58.7,19160,DB00842,Oxazepam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,55.4,19161,DB00842,Oxazepam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,17.2,19162,DB00842,Oxazepam
,6138086,t2,Midazolam shortened (P = 0.025) the sleep latency to first stage 2 (t2 = 29 min) compared with placebo (t2 = 58.7) min and oxazepam (t2 = 55.4 min) in the group of patients; in the group of volunteers t2 was shortened (P = 0.05) only by midazolam (t2 = 17.2 min) compared with placebo (t2 = 24.6 min).,Effect of midazolam on sleep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6138086/),min,24.6,19163,DB00842,Oxazepam
,282778,half-life,The half-life of oxazepam in the newborn averaged 22 hours as compared to 6.5 hours in the mothers.,Pharmacokinetics of oxazepam given during labour. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282778/),h,22,20465,DB00842,Oxazepam
,282778,half-life,The half-life of oxazepam in the newborn averaged 22 hours as compared to 6.5 hours in the mothers.,Pharmacokinetics of oxazepam given during labour. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282778/),h,6.5,20466,DB00842,Oxazepam
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],27.2,24669,DB00842,Oxazepam
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],27.2,24670,DB00842,Oxazepam
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],46.2,24671,DB00842,Oxazepam
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],501,24672,DB00842,Oxazepam
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[mu] / [min],4014601,24673,DB00842,Oxazepam
,10499483,ICG,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[mu] / [min],771,24674,DB00842,Oxazepam
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],46.2,24675,DB00842,Oxazepam
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],501,24676,DB00842,Oxazepam
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[mu] / [min],4014601,24677,DB00842,Oxazepam
,10499483,clearance,"The antipyrine clearance and ICG clearance were significantly decreased in the patients compared with the controls (mean, 27.2 ml/min; 95% confidence interval (CI), 19.4-35; versus 46.2 ml/min; 34.7-58.7, and 501 ml/min; 4014601, versus 771 mU/min; 677-865 (P < 0.05), respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[mu] / [min],771,24678,DB00842,Oxazepam
,10499483,clearance,The oxazepam clearance did not differ significantly between the two groups (181 ml/min (145-217) versus 178 ml/min (152-204)).,"Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],181,24679,DB00842,Oxazepam
,10499483,clearance,The oxazepam clearance did not differ significantly between the two groups (181 ml/min (145-217) versus 178 ml/min (152-204)).,"Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),[ml] / [min],178,24680,DB00842,Oxazepam
,10499483,clearance ratios,"The model drug clearance ratios between the patient and control clearances showed decreased values for antipyrine and ICG compared with the oxazepam data (0.59 and 0.65 versus 1.02, respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),,0.59,24681,DB00842,Oxazepam
,10499483,clearance ratios,"The model drug clearance ratios between the patient and control clearances showed decreased values for antipyrine and ICG compared with the oxazepam data (0.59 and 0.65 versus 1.02, respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),,0.65,24682,DB00842,Oxazepam
,10499483,clearance ratios,"The model drug clearance ratios between the patient and control clearances showed decreased values for antipyrine and ICG compared with the oxazepam data (0.59 and 0.65 versus 1.02, respectively).","Antipyrine, oxazepam, and indocyanine green clearance in patients with chronic pancreatitis and healthy subjects. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499483/),,1.02,24683,DB00842,Oxazepam
,2365292,clearance,The patients showed a severe reduction in the quantitative liver function as assessed by estimation of the clearance of antipyrine; the median value was 9 ml.,Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2365292/),ml,9,26433,DB00842,Oxazepam
,2365292,Apparent clearance,"Apparent clearance of oxazepam in cirrhotic patients was 0.55 ml.min-1.kg-1, with a range of 0.46 to 1.24 ml.min-1.kg-1, compared with 1.19 ml.min-1.kg-1 and a range of 0.80 to 1.66 ml.min-1.kg-1 in the controls (p less than 0.05).",Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2365292/),[ml] / [kg·min],0.55,26434,DB00842,Oxazepam
,2365292,Apparent clearance,"Apparent clearance of oxazepam in cirrhotic patients was 0.55 ml.min-1.kg-1, with a range of 0.46 to 1.24 ml.min-1.kg-1, compared with 1.19 ml.min-1.kg-1 and a range of 0.80 to 1.66 ml.min-1.kg-1 in the controls (p less than 0.05).",Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2365292/),[ml] / [kg·min],1.19,26435,DB00842,Oxazepam
,2365292,unbound clearance,"The unbound clearance of oxazepam in patients was 4.1 ml.min-1.kg-1, with a range of 3.4 to 5.5 ml.",Glucuronidation of oxazepam is not spared in patients with hepatic encephalopathy. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2365292/),[ml] / [kg·min],4.1,26436,DB00842,Oxazepam
,300540,bioavailability,Comparison of plasma concentration time curves after oral and intravenous administration indicated a bioavailability of 70 +/- 15 S.D. %.,First pass conjugation and enterohepatic recycling of oxazepam in dogs; intravenous tolerance of oxazepam in propylene glycol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/300540/),%,70,34885,DB00842,Oxazepam
,7884653,terminal elimination half-life,Results indicated that the elimination of oxazepam from plasma after i.v. injection in both rats and mice were first-order and could be best described by a two-compartment model with a terminal elimination half-life of 4-5 h for rats and 5-7 h for mice.,Toxicokinetics of oxazepam in rats and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884653/),h,4-5,38464,DB00842,Oxazepam
,7884653,terminal elimination half-life,Results indicated that the elimination of oxazepam from plasma after i.v. injection in both rats and mice were first-order and could be best described by a two-compartment model with a terminal elimination half-life of 4-5 h for rats and 5-7 h for mice.,Toxicokinetics of oxazepam in rats and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884653/),h,5-7,38465,DB00842,Oxazepam
<,7884653,bioavailability,"At 50 mg/kg, the bioavailability of oxazepam in rats (< 50%) was lower than in Swiss-Webster mice (> 80%).",Toxicokinetics of oxazepam in rats and mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884653/),%,50,38466,DB00842,Oxazepam
>,7884653,bioavailability,"At 50 mg/kg, the bioavailability of oxazepam in rats (< 50%) was lower than in Swiss-Webster mice (> 80%).",Toxicokinetics of oxazepam in rats and mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884653/),%,80,38467,DB00842,Oxazepam
,7884653,relative bioavailability,"In B6C3F1 mice, the estimated relative bioavailability of oxazepam from dosed feed (relative to gavage study at 50 mg/kg) was about 43%.",Toxicokinetics of oxazepam in rats and mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7884653/),%,43,38468,DB00842,Oxazepam
,19916996,apparent oral clearance,"Median oxazepam apparent oral clearance was significantly lower in 85YY subjects (1.62 ml min(-1) kg(-1)) compared with 85DD subjects (3.35 ml min(-1) kg(-1); P= 0.003, Student-Newman-Keuls test), whereas 85DY subjects were intermediate (2.34 ml min(-1) kg(-1); P= 0.018 vs. 85DD, P= 0.034 vs. 85YY).",Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916996/),[ml] / [kg·min],1.62,47198,DB00842,Oxazepam
,19916996,apparent oral clearance,"Median oxazepam apparent oral clearance was significantly lower in 85YY subjects (1.62 ml min(-1) kg(-1)) compared with 85DD subjects (3.35 ml min(-1) kg(-1); P= 0.003, Student-Newman-Keuls test), whereas 85DY subjects were intermediate (2.34 ml min(-1) kg(-1); P= 0.018 vs. 85DD, P= 0.034 vs. 85YY).",Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916996/),[ml] / [kg·min],3.35,47199,DB00842,Oxazepam
,19916996,apparent oral clearance,"Median oxazepam apparent oral clearance was significantly lower in 85YY subjects (1.62 ml min(-1) kg(-1)) compared with 85DD subjects (3.35 ml min(-1) kg(-1); P= 0.003, Student-Newman-Keuls test), whereas 85DY subjects were intermediate (2.34 ml min(-1) kg(-1); P= 0.018 vs. 85DD, P= 0.034 vs. 85YY).",Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19916996/),[ml] / [kg·min],2.34,47200,DB00842,Oxazepam
,17592586,limit of detections,"The limit of detections of the method from whole blood were 1.7, 1.4 and 2.8 ng mL(-1) for the analysis of diazepam, nordiazepam and oxazepam respectively, and the linear range was from 4 ng mL(-1) to 2 microg mL(-1).",Evaluation of bio-compatible poly(ethylene glycol)-based solid-phase microextraction fiber for in vivo pharmacokinetic studies of diazepam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592586/),[ng] / [ml],1.7,47833,DB00842,Oxazepam
,17592586,limit of detections,"The limit of detections of the method from whole blood were 1.7, 1.4 and 2.8 ng mL(-1) for the analysis of diazepam, nordiazepam and oxazepam respectively, and the linear range was from 4 ng mL(-1) to 2 microg mL(-1).",Evaluation of bio-compatible poly(ethylene glycol)-based solid-phase microextraction fiber for in vivo pharmacokinetic studies of diazepam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592586/),[ng] / [ml],1.4,47834,DB00842,Oxazepam
,17592586,limit of detections,"The limit of detections of the method from whole blood were 1.7, 1.4 and 2.8 ng mL(-1) for the analysis of diazepam, nordiazepam and oxazepam respectively, and the linear range was from 4 ng mL(-1) to 2 microg mL(-1).",Evaluation of bio-compatible poly(ethylene glycol)-based solid-phase microextraction fiber for in vivo pharmacokinetic studies of diazepam in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592586/),[ng] / [ml],2.8,47835,DB00842,Oxazepam
,300542,apparent terminal half-life,The apparent terminal half-life of oxazepam in plasma was 24-91 hours compared to 5.9-25 hours reported elsewhere for healthy volunteers.,Oxazepam disposition in uremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/300542/),h,24-91,48206,DB00842,Oxazepam
,300542,apparent terminal half-life,The apparent terminal half-life of oxazepam in plasma was 24-91 hours compared to 5.9-25 hours reported elsewhere for healthy volunteers.,Oxazepam disposition in uremic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/300542/),h,5.9-25,48207,DB00842,Oxazepam
,300542,urinary recovery,The urinary recovery over 5 days was 18-57%.,Oxazepam disposition in uremic patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/300542/),%,18-57,48208,DB00842,Oxazepam
,300542,faecal recovery,The faecal recovery of 3 days was 0.1-19%.,Oxazepam disposition in uremic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/300542/),%,0.1-19,48209,DB00842,Oxazepam
,18536153,flow rate,"The chromatographic separation was accomplished using a 125 x 4-mm (inner diameter) stainless-steel (5 microm) Perfectsil Target ODS-3 reversed phase column with a mobile phase consisting of ammonium dihydrogen phosphate buffer (0.05 mol x L(-1), pH 5.8) and methanol (50:50, v/v), running at a flow rate of 1.5 ml x min(-1).",New high-performance liquid chromatographic method for serum analysis of oxazepam: application to bioequivalence and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18536153/),[ml] / [min],1.5,48535,DB00842,Oxazepam
,32219697,time of maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,1.04,48787,DB00842,Oxazepam
,32219697,time of maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,133.14,48788,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],87.37,48789,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,129.07,48790,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,133.14,48791,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],3.80,48792,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,100.29,48793,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.62,48794,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,44.43,48795,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,66.86,48796,DB00842,Oxazepam
,32219697,maximum concentration,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.10,48797,DB00842,Oxazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,129.07,48798,DB00842,Oxazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,382.86,48799,DB00842,Oxazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,44.43,48800,DB00842,Oxazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],2.08,48801,DB00842,Oxazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,130.53,48802,DB00842,Oxazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,66.86,48803,DB00842,Oxazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),[ng] / [ml],1.10,48804,DB00842,Oxazepam
,32219697,elimination half-life,"The respective time of maximum concentration, the maximum concentration and the elimination half-life of diazepam were 1.04 ± 1.00 h, 87.37 ± 31.92 ng/mL and 129.07 ± 75.00 h; of nordazepam were 133.14 ± 109.63 h, 3.80 ± 1.75 ng/mL, and 229.73 ± 236.83 h; of oxazepam were 100.29 ± 87.16 h, 1.62 ± 2.64 ng/mL, and 382.86 ± 324.58 h; of temazepam glucuronide were 44.43 ± 55.41 h, 2.08 ± 0.88 ng/mL, and 130.53 ± 72.11 h; and of oxazepam glucuronide were 66.86 ± 56.33 h, 1.10 ± 0.41 ng/mL, and 240.66 ± 170.12 h.",Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219697/),h,240.66,48805,DB00842,Oxazepam
,6111408,elimination half-life,"Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),h,5 to 15,51388,DB00842,Oxazepam
,6111408,volume of distribution,"Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),[l] / [kg],0.6 to 2.0,51389,DB00842,Oxazepam
,6111408,clearance,"Usual ranges for kinetic parameters are: elimination half-life, 5 to 15 hours; volume of distribution, 0.6 to 2.0 L/kg; clearance, 0.9 to 2.0 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),[ml] / [kg·min],0.9 to 2.0,51390,DB00842,Oxazepam
,6111408,elimination half-life,"Typical kinetic values for lorazepam are: elimination half-life, 8 to 25 hours; volume of distribution, 1.0 to 1.3 L/kg; clearance, 0.7 to 1.2 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),h,8 to 25,51391,DB00842,Oxazepam
,6111408,volume of distribution,"Typical kinetic values for lorazepam are: elimination half-life, 8 to 25 hours; volume of distribution, 1.0 to 1.3 L/kg; clearance, 0.7 to 1.2 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),[l] / [kg],1.0 to 1.3,51392,DB00842,Oxazepam
,6111408,clearance,"Typical kinetic values for lorazepam are: elimination half-life, 8 to 25 hours; volume of distribution, 1.0 to 1.3 L/kg; clearance, 0.7 to 1.2 ml/min/kg.",Clinical pharmacokinetics of oxazepam and lorazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),[ml] / [kg·min],0.7 to 1.2,51393,DB00842,Oxazepam
,6111408,systemic availability,"Oral and intramuscular lorazepam are rapidly absorbed, with systemic availability averaging 90% or more.",Clinical pharmacokinetics of oxazepam and lorazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),%,90,51394,DB00842,Oxazepam
,6111408,free fraction,"Both oxazepam and lorazepam are extensively bound to plasma protein, but the free fraction for lorazepam (8 to 12%) is greater than that for oxazepam (2 to 4%).",Clinical pharmacokinetics of oxazepam and lorazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),%,8 to 12,51395,DB00842,Oxazepam
,6111408,free fraction,"Both oxazepam and lorazepam are extensively bound to plasma protein, but the free fraction for lorazepam (8 to 12%) is greater than that for oxazepam (2 to 4%).",Clinical pharmacokinetics of oxazepam and lorazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111408/),%,2 to 4,51396,DB00842,Oxazepam
,21219339,bioavailability,"The bioavailability of diazepam after i.n. drop and atomized nasal administration was 42% and 41%, respectively.",Diazepam pharmacokinetics after nasal drop and atomized nasal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219339/),%,42,54279,DB00842,Oxazepam
,21219339,bioavailability,"The bioavailability of diazepam after i.n. drop and atomized nasal administration was 42% and 41%, respectively.",Diazepam pharmacokinetics after nasal drop and atomized nasal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219339/),%,41,54280,DB00842,Oxazepam
,6482312,elimination half-life,"Based on total (free plus bound) serum oxazepam concentrations, elimination half-life was prolonged in renal patients compared to controls (22 vs 8 h, p less than 0.001) and volume of distribution increased (3.0 vs 1.4 1/kg, p less than 0.02).",Disposition of oxazepam in patients on maintenance hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6482312/),h,22,54730,DB00842,Oxazepam
,6482312,elimination half-life,"Based on total (free plus bound) serum oxazepam concentrations, elimination half-life was prolonged in renal patients compared to controls (22 vs 8 h, p less than 0.001) and volume of distribution increased (3.0 vs 1.4 1/kg, p less than 0.02).",Disposition of oxazepam in patients on maintenance hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6482312/),h,8,54731,DB00842,Oxazepam
,6482312,volume of distribution,"Based on total (free plus bound) serum oxazepam concentrations, elimination half-life was prolonged in renal patients compared to controls (22 vs 8 h, p less than 0.001) and volume of distribution increased (3.0 vs 1.4 1/kg, p less than 0.02).",Disposition of oxazepam in patients on maintenance hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6482312/),[1] / [kg],3.0,54732,DB00842,Oxazepam
,6482312,volume of distribution,"Based on total (free plus bound) serum oxazepam concentrations, elimination half-life was prolonged in renal patients compared to controls (22 vs 8 h, p less than 0.001) and volume of distribution increased (3.0 vs 1.4 1/kg, p less than 0.02).",Disposition of oxazepam in patients on maintenance hemodialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6482312/),[1] / [kg],1.4,54733,DB00842,Oxazepam
,6482312,total clearance,"However, total clearance was similar between groups (1.8 vs 1.9 ml/min per kilogram).",Disposition of oxazepam in patients on maintenance hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6482312/),[ml] / [kg·min],1.8,54734,DB00842,Oxazepam
,6482312,total clearance,"However, total clearance was similar between groups (1.8 vs 1.9 ml/min per kilogram).",Disposition of oxazepam in patients on maintenance hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6482312/),[ml] / [kg·min],1.9,54735,DB00842,Oxazepam
,6482312,clearance,"Correction for differences in binding indicates similar distribution of unbound oxazepam between groups, but reduced clearance of pharmacologically active unbound oxazepam in renal patients (18 vs 45 ml/min per kilogram).",Disposition of oxazepam in patients on maintenance hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6482312/),[ml] / [kg·min],18,54736,DB00842,Oxazepam
,6482312,clearance,"Correction for differences in binding indicates similar distribution of unbound oxazepam between groups, but reduced clearance of pharmacologically active unbound oxazepam in renal patients (18 vs 45 ml/min per kilogram).",Disposition of oxazepam in patients on maintenance hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6482312/),[ml] / [kg·min],45,54737,DB00842,Oxazepam
,26580099,clearance,"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),[l] / [h],6.8,54824,DB00842,Oxazepam
,26580099,apparent volume of distribution (V),"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),l,159,54825,DB00842,Oxazepam
,26580099,duration of absorption (D1),"The population typical mean 90% confidence interval values for clearance, apparent volume of distribution (V), and duration of absorption (D1) were 6.8 L/h (range, 3.9-8.0 L/h), 159 L (range, 98.0-282 L), and 2 hours (fixed), respectively.",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),h,2,54826,DB00842,Oxazepam
,26580099,elimination half-life,"The elimination half-life was 16 hours (range, 3-42 hours).",Population Pharmacokinetics of High-Dose Oxazepam in Alcohol-Dependent Patients: Is There a Risk of Accumulation? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26580099/),h,16,54827,DB00842,Oxazepam
,16112623,flow-rate,"Chromatographic separation was performed on a reversed-phase Synergi Max RP analytical column (150 mmx4.6 mm i.d.; 4 microm particle size), using an aqueous mobile phase (10 mM KH2PO4 buffer (pH 2.4)-acetonitrile; 65:35%, v/v) delivered at a flow-rate of 2.5 ml/min.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),[ml] / [min],2.5,61951,DB00842,Oxazepam
,16112623,Retention times,"Retention times for OZP and LZP were 10.2 and 11.9 min, respectively.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),min,10.2,61952,DB00842,Oxazepam
,16112623,Retention times,"Retention times for OZP and LZP were 10.2 and 11.9 min, respectively.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),min,11.9,61953,DB00842,Oxazepam
,16112623,limits of detection (LOD),"The limits of detection (LOD) and quantification (LOQ) were 2.5 and 10 ng/ml, respectively, using 0.5 ml samples.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),[ng] / [ml],2.5,61954,DB00842,Oxazepam
,16112623,quantification (LOQ),"The limits of detection (LOD) and quantification (LOQ) were 2.5 and 10 ng/ml, respectively, using 0.5 ml samples.",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),[ng] / [ml],10,61955,DB00842,Oxazepam
,16112623,relative recoveries,"The mean relative recoveries at 20 and 300 ng/ml were 84.1+/-5.5% (n=6) and 72.4+/-5.9% (n=7), respectively; for OZP at 200 ng the value was 68.2+/-6.8% (n=14).",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),%,84.1,61956,DB00842,Oxazepam
,16112623,relative recoveries,"The mean relative recoveries at 20 and 300 ng/ml were 84.1+/-5.5% (n=6) and 72.4+/-5.9% (n=7), respectively; for OZP at 200 ng the value was 68.2+/-6.8% (n=14).",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),%,72.4,61957,DB00842,Oxazepam
,16112623,relative recoveries,"The mean relative recoveries at 20 and 300 ng/ml were 84.1+/-5.5% (n=6) and 72.4+/-5.9% (n=7), respectively; for OZP at 200 ng the value was 68.2+/-6.8% (n=14).",Determination of lorazepam in plasma from children by high-performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16112623/),%,68.2,61958,DB00842,Oxazepam
,6147314,Absorption rate constant,Absorption rate constant and peak plasma levels of pinazepam were 1.36 +/- 0.15 h-1 and 36.8 +/- 5.1 ng/ml respectively.,Pharmacokinetics of pinazepam in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6147314/),1/[h],1.36,65792,DB00842,Oxazepam
,6147314,peak plasma levels,Absorption rate constant and peak plasma levels of pinazepam were 1.36 +/- 0.15 h-1 and 36.8 +/- 5.1 ng/ml respectively.,Pharmacokinetics of pinazepam in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6147314/),[ng] / [ml],36.8,65793,DB00842,Oxazepam
,6147314,alpha,Plasma decay of the drug consisted of an initial rapid elimination phase (alpha = 0.46 +/- 0.06 h-1) followed by a slow one (beta = 0.046 +/- 0.004 h-1).,Pharmacokinetics of pinazepam in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6147314/),1/[h],0.46,65794,DB00842,Oxazepam
,6147314,beta,Plasma decay of the drug consisted of an initial rapid elimination phase (alpha = 0.46 +/- 0.06 h-1) followed by a slow one (beta = 0.046 +/- 0.004 h-1).,Pharmacokinetics of pinazepam in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6147314/),1/[h],0.046,65795,DB00842,Oxazepam
,6144699,elimination half-life,"Cimetidine likewise did not alter the elimination half-life of oxazepam (9.4 hours) or lorazepam (11.6 hours), and did not change total AUC for lorazepam.","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,9.4,66643,DB00842,Oxazepam
,6144699,elimination half-life,"Cimetidine likewise did not alter the elimination half-life of oxazepam (9.4 hours) or lorazepam (11.6 hours), and did not change total AUC for lorazepam.","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,11.6,66644,DB00842,Oxazepam
,6144699,elimination half-life,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,141,66645,DB00842,Oxazepam
,6144699,elimination half-life,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),h,94,66646,DB00842,Oxazepam
,6144699,AUC,"In contrast, cimetidine prolonged desalkylflurazepam elimination half-life (141 vs. 94 hours, P less than 0.1) and increased AUC an average of 65 per cent (P less than 0.05).","Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144699/),-1,65,66647,DB00842,Oxazepam
,15234378,apparent half-life,"The neonatal blood concentrations of the clorazepate metabolites were very high at delivery (26 mg/l nordiazepam and 3.5 mg/l oxazepam) and showed little change over the next 5 days (16 mg/l nordiazepam and 2.1 mg/l oxazepam, with an apparent half-life of 168 h for nordiazepam and 160 h for oxazepam).",[Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234378/),h,168,67971,DB00842,Oxazepam
,15234378,apparent half-life,"The neonatal blood concentrations of the clorazepate metabolites were very high at delivery (26 mg/l nordiazepam and 3.5 mg/l oxazepam) and showed little change over the next 5 days (16 mg/l nordiazepam and 2.1 mg/l oxazepam, with an apparent half-life of 168 h for nordiazepam and 160 h for oxazepam).",[Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234378/),h,160,67972,DB00842,Oxazepam
,15234378,half-lifes,The nordiazepam and oxazepam half-lifes were reduced to 42 h and 30 h respectively.,[Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234378/),h,42,67973,DB00842,Oxazepam
,15234378,half-lifes,The nordiazepam and oxazepam half-lifes were reduced to 42 h and 30 h respectively.,[Benzodiazepine poisoning in a neonate: clinical and toxicokinetic evaluation following enterodialysis with activated charcoal]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15234378/),h,30,67974,DB00842,Oxazepam
,43552,elimination half-life,Values of elimination half-life ranged from 8.3--31.2 h (mean 17.0 h) and did not vary significantly with dose.,"Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/43552/),h,17.0,69442,DB00842,Oxazepam
,43552,observed accumulation ratio,"The mean observed accumulation ratio was 1.84, which was slightly larger than the predicted ratio of 1.53.","Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43552/),,1.84,69443,DB00842,Oxazepam
,6790396,elimination half life,"The time course of the active metabolite descyclopropylmethylprazepam (= norprazepam), representing 80-90% of all prazepam metabolites in plasma, can be described by an open one compartment model with a mean elimination half life of 70 h and a plasma clearance of 1.0-1.4 l/h.",[Pharmacokinetics of oral prazepam]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6790396/),h,70,73119,DB00842,Oxazepam
,6790396,plasma clearance,"The time course of the active metabolite descyclopropylmethylprazepam (= norprazepam), representing 80-90% of all prazepam metabolites in plasma, can be described by an open one compartment model with a mean elimination half life of 70 h and a plasma clearance of 1.0-1.4 l/h.",[Pharmacokinetics of oral prazepam]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6790396/),[l] / [h],1.0-1.4,73120,DB00842,Oxazepam
,6790396,peak levels,"3-5 h after single doses of 20 mg prazepam, the corresponding peak levels of norprazepam are 120-160 ng/ml.",[Pharmacokinetics of oral prazepam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6790396/),[ng] / [ml],120-160,73121,DB00842,Oxazepam
,6790396,steady state levels,Following repeated doses of daily 20 mg prazepam steady state levels of norprazepam are 600-800 ng/ml.,[Pharmacokinetics of oral prazepam]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6790396/),[ng] / [ml],600-800,73122,DB00842,Oxazepam
shorter,22929751,elimination half-life,"In theory, accumulation does not occur with once-daily dosage of benzodiazepines that have an elimination half-life markedly shorter than 24 h, such as oxazepam, temazepam, and lorazepam.",[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22929751/),h,24,77548,DB00842,Oxazepam
,9811432,peak plasma concentrations,"Mean peak plasma concentrations after i.v. administration were 5963 and 5565 ng/mL, before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],5963,81953,DB00842,Oxazepam
,9811432,peak plasma concentrations,"Mean peak plasma concentrations after i.v. administration were 5963 and 5565 ng/mL, before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],5565,81954,DB00842,Oxazepam
,9811432,peak concentrations,"After p.r. administration, mean peak concentrations were 629 ng/mL and 274 ng/mL and were reached within 30 min before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],629,81955,DB00842,Oxazepam
,9811432,peak concentrations,"After p.r. administration, mean peak concentrations were 629 ng/mL and 274 ng/mL and were reached within 30 min before and after phenobarbital treatment, respectively.",Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),[ng] / [ml],274,81956,DB00842,Oxazepam
,9811432,time to attainment of target concentration,The target concentration for potential seizure control (i.e. 150 ng/mL) was attained in five dogs in the post phenobarbital p.r. group with a median time to attainment of target concentration of 8 min.,Chronic phenobarbital therapy reduces plasma benzodiazepine concentrations after intravenous and rectal administration of diazepam in the dog. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9811432/),min,8,81957,DB00842,Oxazepam
,7130314,minimum detection range,The minimum detection range of each compound was approximately 2.5 ng per 100-microliter sample.,Determination of diazepam and its pharmacologically active metabolites in blood by bond Elut column extraction and reversed-phase high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7130314/),-1·ng,2.5,82713,DB00842,Oxazepam
,34115414,plasma clearance,"The mean plasma clearance of DIA was 5.9 ml/min/kg, and the plasma elimination half-life in the terminal phase was 19.9 h.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),[ml] / [kg·min],5.9,83712,DB00842,Oxazepam
,34115414,plasma elimination half-life in the terminal phase,"The mean plasma clearance of DIA was 5.9 ml/min/kg, and the plasma elimination half-life in the terminal phase was 19.9 h.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),h,19.9,83713,DB00842,Oxazepam
,34115414,detection time,"The detection time according to the European Horserace Scientific Liaison Committee (EHSLC), that is the time for which observed DIA plasma concentrations of all investigated horses were below the IPC was 10 days.",Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34115414/),d,10,83714,DB00842,Oxazepam
,6780369,elimination half-life,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),h,51.7,85671,DB00842,Oxazepam
,6780369,elimination half-life,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),h,72.6,85672,DB00842,Oxazepam
,6780369,total plasma clearance,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),[ml] / [min],12.0,85673,DB00842,Oxazepam
,6780369,total plasma clearance,"Cimetidine significantly impaired (p = 0.03) the elimination of desmethyldiazepam, as shown prolongation of its elimination half-life from 51.7 +/- 21.9 h to 72.6 +/- 39.4 h (mean +/- SD), and a decrease in total plasma clearance from 12.0 +/- 2.7 ml/min to 8.6 +/- 3.3 ml/min.",Influence of cimetidine on the pharmacokinetics of desmethyldiazepam and oxazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6780369/),[ml] / [min],8.6,85674,DB00842,Oxazepam
,6132698,volume of distribution (Vd),"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.33,85924,DB00842,Oxazepam
,6132698,volume of distribution (Vd),"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.45,85925,DB00842,Oxazepam
,6132698,elimination t1/2,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,13.1,85926,DB00842,Oxazepam
,6132698,elimination t1/2,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,12.2,85927,DB00842,Oxazepam
,6132698,total clearance,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.25,85928,DB00842,Oxazepam
,6132698,total clearance,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.50,85929,DB00842,Oxazepam
,6132698,free fraction in,"Mean kinetic variables for lorazepam in control and OC groups (n = 15 in each group) were: volume of distribution (Vd), 1.33 and 1.45 l/kg; elimination t1/2, 13.1 and 12.2 hr; total clearance, 1.25 and 1.50 ml/min/kg; free fraction in plasma, 10.3% and 10.3% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,10.3,85930,DB00842,Oxazepam
,6132698,Vd,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.05,85931,DB00842,Oxazepam
,6132698,Vd,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[l] / [kg],1.19,85932,DB00842,Oxazepam
,6132698,t1/2,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,7.6,85933,DB00842,Oxazepam
,6132698,t1/2,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),h,7.2,85934,DB00842,Oxazepam
,6132698,total clearance,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],1.60,85935,DB00842,Oxazepam
,6132698,total clearance,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),[ml] / [kg·min],2.03,85936,DB00842,Oxazepam
,6132698,free fraction,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,4.6,85937,DB00842,Oxazepam
,6132698,free fraction,"For oxazepam, kinetic variables in the two groups (n = 14 and 17) were: Vd, 1.05 and 1.19 l/kg; t1/2, 7.6 and 7.2 hr; total clearance, 1.60 and 2.03 ml/min/kg; free fraction, 4.6% and 4.9% unbound.",Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132698/),%,4.9,85938,DB00842,Oxazepam
,7452494,peak plasma levels,Absorption of oxazepam was relatively slow with peak plasma levels reached an average of 2 to 3 hr after dosage.,Oxazepam kinetics: effects of age and sex. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),h,2 to 3,89133,DB00842,Oxazepam
,7452494,Elimination half-life,Elimination half-life ranged from 4.9 to 19.4 hr and was longer (P < .05) in females (mean: 9.7 hr) than in males (7.8 hr).,Oxazepam kinetics: effects of age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),h,4.9 to 19.4,89134,DB00842,Oxazepam
,7452494,Elimination half-life,Elimination half-life ranged from 4.9 to 19.4 hr and was longer (P < .05) in females (mean: 9.7 hr) than in males (7.8 hr).,Oxazepam kinetics: effects of age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),h,9.7,89135,DB00842,Oxazepam
,7452494,Elimination half-life,Elimination half-life ranged from 4.9 to 19.4 hr and was longer (P < .05) in females (mean: 9.7 hr) than in males (7.8 hr).,Oxazepam kinetics: effects of age and sex. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),h,7.8,89136,DB00842,Oxazepam
,7452494,free fraction,The mean free fraction was 4.3% and did not differ between sexes.,Oxazepam kinetics: effects of age and sex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452494/),%,4.3,89137,DB00842,Oxazepam
,8085287,plasma IP,"Initial plasma IP level was 2260 ng/ml, whole blood total cyclosporine (T-CsA) concentration was 1,800 ng/ml and that of specific cyclosporine (Sp-CsA), 714 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],714,90235,DB00842,Oxazepam
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],232,90236,DB00842,Oxazepam
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],401,90237,DB00842,Oxazepam
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],96,90238,DB00842,Oxazepam
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,43.4,90239,DB00842,Oxazepam
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,70.1,90240,DB00842,Oxazepam
,7337498,elimination half-life t0.5(beta),"After i.v. administration of 2 mg/kg diazepam to dogs, concentrations of unmetabolized drug showed a triexponential decline with an average elimination half-life t0.5(beta) of 3.2 hr.",Pharmacokinetics of diazepam in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),h,3.2,103264,DB00842,Oxazepam
,7337498,Elimination half-lives,Elimination half-lives of this metabolite averaged 3.6 hr.,Pharmacokinetics of diazepam in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),h,3.6,103265,DB00842,Oxazepam
,7337498,maximal plasma concentrations,Oxazepam reached maximal plasma concentrations in the range of 100 ng/ml after about 2 hr which then declined with a half-life of 5.7 hr.,Pharmacokinetics of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),[ng] / [ml],100,103266,DB00842,Oxazepam
,7337498,half-life,Oxazepam reached maximal plasma concentrations in the range of 100 ng/ml after about 2 hr which then declined with a half-life of 5.7 hr.,Pharmacokinetics of diazepam in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),h,5.7,103267,DB00842,Oxazepam
,7337498,Oral bioavailability,Oral bioavailability was in the range of 74-100%.,Pharmacokinetics of diazepam in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),%,74-100,103268,DB00842,Oxazepam
,7337498,steady state plasma concentrations,By continued oral administration of 1 or 2 mg/kg diazepam t.i.d. it was possible to maintain steady state plasma concentrations of 1000-2000 ng/ml desmethyldiazepam and maximal diazepam concentrations of 100-800 ng/ml.,Pharmacokinetics of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),[ng] / [ml],1000-2000,103269,DB00842,Oxazepam
,7337498,maximal diazepam concentrations,By continued oral administration of 1 or 2 mg/kg diazepam t.i.d. it was possible to maintain steady state plasma concentrations of 1000-2000 ng/ml desmethyldiazepam and maximal diazepam concentrations of 100-800 ng/ml.,Pharmacokinetics of diazepam in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337498/),[ng] / [ml],100-800,103270,DB00842,Oxazepam
,2271373,total,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],0.78,104635,DB00842,Oxazepam
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],1.22,104636,DB00842,Oxazepam
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],9.3,104637,DB00842,Oxazepam
,2271373,unbound clearance,"2. The median total and unbound clearance of oxazepam increased significantly during the study period from 0.78 ml min-1 kg-1 (0.40-1.25) to 1.22 ml min-1 kg-1 (0.66-1.94) and from 9.3 ml min-1 kg-1 (5.2-14.2) to 15.9 ml min-1 kg-1 (7.8-21.8), respectively (P less than 0.01).",Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],15.9,104638,DB00842,Oxazepam
,2271373,elimination half-life,3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),h,9.3,104639,DB00842,Oxazepam
,2271373,elimination half-life,3. The elimination half-life of oxazepam was prolonged by hypothyroidism to a median (range) value of 9.3 h (5.4-21.9) compared with 7.5 h (4.8-10.5) in the euthyroid state (P less than 0.05).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),h,7.5,104640,DB00842,Oxazepam
,2271373,free percentage,4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),%,8.2,104641,DB00842,Oxazepam
,2271373,free percentage,4. Hypothyroidism did not affect the protein binding of oxazepam; median values of the free percentage being 8.2% as compared with 7.7% when euthyroid.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),%,7.7,104642,DB00842,Oxazepam
,2271373,clearance,5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],3.12,104643,DB00842,Oxazepam
,2271373,clearance,5. The median (range) clearance of paracetamol under hypothyroid conditions was 3.12 ml min-1 kg-1 (1.64-4.40) and 4.70 ml min-1 kg-1 (3.18-5.70) following replacement therapy (P less than 0.01).,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],4.70,104644,DB00842,Oxazepam
,2271373,partial clearance,This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],1.86,104645,DB00842,Oxazepam
,2271373,partial clearance,This increase was associated with a comparable increase in the partial clearance to the glucuronide metabolite: 1.86 ml min-1 kg-1 to 2.70 ml min-1 kg-1.,Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271373/),[ml] / [kg·min],2.70,104646,DB00842,Oxazepam
,7278081,elimination half-life,"Mean kinetic variables in males and females, respectively, were: elimination half-life, 7.5 and 8.5 h; volume of distribution, 0.96 and 1.17 l/kg; clearance, 1.48 and 1.70 ml/min/kg.","Disposition of oxazepam in relation to age, sex, and cigarette smoking. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7278081/),h,7.5,112747,DB00842,Oxazepam
,7278081,elimination half-life,"Mean kinetic variables in males and females, respectively, were: elimination half-life, 7.5 and 8.5 h; volume of distribution, 0.96 and 1.17 l/kg; clearance, 1.48 and 1.70 ml/min/kg.","Disposition of oxazepam in relation to age, sex, and cigarette smoking. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7278081/),h,8.5,112748,DB00842,Oxazepam
,7278081,volume of distribution,"Mean kinetic variables in males and females, respectively, were: elimination half-life, 7.5 and 8.5 h; volume of distribution, 0.96 and 1.17 l/kg; clearance, 1.48 and 1.70 ml/min/kg.","Disposition of oxazepam in relation to age, sex, and cigarette smoking. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7278081/),[l] / [kg],0.96,112749,DB00842,Oxazepam
,7278081,volume of distribution,"Mean kinetic variables in males and females, respectively, were: elimination half-life, 7.5 and 8.5 h; volume of distribution, 0.96 and 1.17 l/kg; clearance, 1.48 and 1.70 ml/min/kg.","Disposition of oxazepam in relation to age, sex, and cigarette smoking. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7278081/),[l] / [kg],1.17,112750,DB00842,Oxazepam
,7278081,clearance,"Mean kinetic variables in males and females, respectively, were: elimination half-life, 7.5 and 8.5 h; volume of distribution, 0.96 and 1.17 l/kg; clearance, 1.48 and 1.70 ml/min/kg.","Disposition of oxazepam in relation to age, sex, and cigarette smoking. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7278081/),[ml] / [kg·min],1.48,112751,DB00842,Oxazepam
,7278081,clearance,"Mean kinetic variables in males and females, respectively, were: elimination half-life, 7.5 and 8.5 h; volume of distribution, 0.96 and 1.17 l/kg; clearance, 1.48 and 1.70 ml/min/kg.","Disposition of oxazepam in relation to age, sex, and cigarette smoking. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7278081/),[ml] / [kg·min],1.70,112752,DB00842,Oxazepam
,7278081,clearance,"Mean clearance in smokers (1.98 ml/min/kg) was significantly higher than in nonsmokers (1.23 ml/min/kg, p less than 0.01).","Disposition of oxazepam in relation to age, sex, and cigarette smoking. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7278081/),[ml] / [kg·min],1.98,112753,DB00842,Oxazepam
,7278081,clearance,"Mean clearance in smokers (1.98 ml/min/kg) was significantly higher than in nonsmokers (1.23 ml/min/kg, p less than 0.01).","Disposition of oxazepam in relation to age, sex, and cigarette smoking. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7278081/),[ml] / [kg·min],1.23,112754,DB00842,Oxazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),μg,9.7,117994,DB00842,Oxazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),μg,243,117995,DB00842,Oxazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),[ng] / [g],3.75,117996,DB00842,Oxazepam
,8166961,Residue concentrations,"Residue concentrations were reduced from 9.7 and 243 micrograms in consumed guinea pig liver to 3.75 and 455 ng/g in rat liver for parent drug and oxazepam, the lowest and highest residues found, respectively.",Bioavailability of residues of diazepam and its metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8166961/),[ng] / [g],455,117997,DB00842,Oxazepam
greater,1871049,half-life,"Products chosen fulfilled one of the following three criteria: (1) a high ""apparent intrasubject variability"" and a half-life greater than 8 hr (danazol); (2) a low apparent intrasubject variability and a half-life less than 4 hr (baclofen); and (3) products exhibiting a low apparent intrasubject variability and a half-life greater than 8 hr (oxazepam).",Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1871049/),h,8,123998,DB00842,Oxazepam
less,1871049,half-life,"Products chosen fulfilled one of the following three criteria: (1) a high ""apparent intrasubject variability"" and a half-life greater than 8 hr (danazol); (2) a low apparent intrasubject variability and a half-life less than 4 hr (baclofen); and (3) products exhibiting a low apparent intrasubject variability and a half-life greater than 8 hr (oxazepam).",Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1871049/),h,4,123999,DB00842,Oxazepam
less,1871049,elimination half-life,"On the other hand, AUCO-LAST worked best with a high fractional standard deviation (fsd) and a short elimination half-life (i.e., less than 4 hr).",Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1871049/),h,4,124000,DB00842,Oxazepam
,29682729,Vd,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),ml,608,124751,DB00842,Oxazepam
,29682729,CL,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124752,DB00842,Oxazepam
,29682729,CL,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124753,DB00842,Oxazepam
,29682729,t1/2α (,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124754,DB00842,Oxazepam
,29682729,t1/2α (,"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124755,DB00842,Oxazepam
,29682729,distribution half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ml] / [min],22.1,124756,DB00842,Oxazepam
,29682729,distribution half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,13.7,124757,DB00842,Oxazepam
,29682729,t1/2β (terminal half-life),"The derived parameters Vd , CL, t1/2α (distribution half-life) and t1/2β (terminal half-life) for diazepam were, respectively, 608 mL, 22.1 mL/min, 13.7 minutes, and 76.8 minutes, respectively.",Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),min,76.8,124758,DB00842,Oxazepam
,29682729,minimal plasma diazepam concentration,The minimal plasma diazepam concentration associated with threshold elevations was estimated at approximately 70 ng/mL.,Determination of minimal steady-state plasma level of diazepam causing seizure threshold elevation in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29682729/),[ng] / [ml],70,124759,DB00842,Oxazepam
,20375123,peak serum concentrations,"For temazepam and oxazepam, peak serum concentrations were 8.5 and 1.3 mg/L, respectively.",Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375123/),[mg] / [l],8.5,131399,DB00842,Oxazepam
,20375123,peak serum concentrations,"For temazepam and oxazepam, peak serum concentrations were 8.5 and 1.3 mg/L, respectively.",Toxicokinetics of a dipyridamole (Persantin) intoxication: case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20375123/),[mg] / [l],1.3,131400,DB00842,Oxazepam
,1685875,half-lives,half-lives of 30-40 min were determined for the beta-phase and 8-10 h for the terminal elimination phase (Table 2).,[The pharmacokinetics of lormetazepam following cimetidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685875/),min,30-40,140482,DB00842,Oxazepam
,1685875,half-lives,half-lives of 30-40 min were determined for the beta-phase and 8-10 h for the terminal elimination phase (Table 2).,[The pharmacokinetics of lormetazepam following cimetidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1685875/),h,8-10,140483,DB00842,Oxazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,56-135,142641,DB00842,Oxazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,35-116,142642,DB00842,Oxazepam
,2882760,uptake ratios,"Highest uptake ratios relative to free (unbound) drug in plasma were in adrenal (56-135), liver (35-116) and kidney (19-50).","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,19-50,142643,DB00842,Oxazepam
,2882760,Free fraction,"Free fraction in plasma varied from 0.13 for desmethyldiazepam to 0.30 for triazolam, and was unrelated to age.","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,0.13,142644,DB00842,Oxazepam
,2882760,Free fraction,"Free fraction in plasma varied from 0.13 for desmethyldiazepam to 0.30 for triazolam, and was unrelated to age.","Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882760/),,0.30,142645,DB00842,Oxazepam
,4041343,peak plasma concentration,"During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +/- 18 ng ml-1 (mean +/- s.e. mean) to 241 +/- 10 ng ml-1 and total area under the plasma concentration-time curve (AUC) significantly decreased from 5536 +/- 819 ng ml-1 h to 4643 +/- 562 ng ml-1 h.",The influence of diflunisal on the pharmacokinetics of oxazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[ng] / [ml],387,151725,DB00842,Oxazepam
,4041343,peak plasma concentration,"During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +/- 18 ng ml-1 (mean +/- s.e. mean) to 241 +/- 10 ng ml-1 and total area under the plasma concentration-time curve (AUC) significantly decreased from 5536 +/- 819 ng ml-1 h to 4643 +/- 562 ng ml-1 h.",The influence of diflunisal on the pharmacokinetics of oxazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[ng] / [ml],241,151726,DB00842,Oxazepam
,4041343,total area under the plasma concentration-time curve (AUC),"During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +/- 18 ng ml-1 (mean +/- s.e. mean) to 241 +/- 10 ng ml-1 and total area under the plasma concentration-time curve (AUC) significantly decreased from 5536 +/- 819 ng ml-1 h to 4643 +/- 562 ng ml-1 h.",The influence of diflunisal on the pharmacokinetics of oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[h·ng] / [ml],5536,151727,DB00842,Oxazepam
,4041343,total area under the plasma concentration-time curve (AUC),"During diflunisal treatment, peak plasma concentration of oxazepam significantly decreased from 387 +/- 18 ng ml-1 (mean +/- s.e. mean) to 241 +/- 10 ng ml-1 and total area under the plasma concentration-time curve (AUC) significantly decreased from 5536 +/- 819 ng ml-1 h to 4643 +/- 562 ng ml-1 h.",The influence of diflunisal on the pharmacokinetics of oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[h·ng] / [ml],4643,151728,DB00842,Oxazepam
,4041343,AUC,The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10.0 +/- 0.6 h to 13.0 +/- 1.0 h.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[h·ng] / [ml],4771,151729,DB00842,Oxazepam
,4041343,AUC,The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10.0 +/- 0.6 h to 13.0 +/- 1.0 h.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[h·ng] / [ml],8116,151730,DB00842,Oxazepam
,4041343,elimination half-life,The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10.0 +/- 0.6 h to 13.0 +/- 1.0 h.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),h,10.0,151731,DB00842,Oxazepam
,4041343,elimination half-life,The AUC of oxazepam glucuronide significantly increased from 4771 +/- 227 ng ml-1 h to 8116 +/- 644 ng ml-1 h and its elimination half-life increased from 10.0 +/- 0.6 h to 13.0 +/- 1.0 h.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),h,13.0,151732,DB00842,Oxazepam
,4041343,Renal clearance,Renal clearance for oxazepam glucuronide was significantly reduced from 74 +/- 2 ml min-1 to 46 +/- 3 ml min-1.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[ml] / [min],74,151733,DB00842,Oxazepam
,4041343,Renal clearance,Renal clearance for oxazepam glucuronide was significantly reduced from 74 +/- 2 ml min-1 to 46 +/- 3 ml min-1.,The influence of diflunisal on the pharmacokinetics of oxazepam. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041343/),[ml] / [min],46,151734,DB00842,Oxazepam
,6132989,half-life,"Elimination of the radioactive dose was rapid during 0-8 hr, with a half-life of approximately 1 hr.",Biliary excretion of [14C]temazepam and its metabolites in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6132989/),h,1,155200,DB00842,Oxazepam
,362051,half-life (T1/2(beta)),"While the normal half-life (T1/2(beta)) varies between 1 and 2 days, it can be increased to up to 80--100 h in subjects over 60 years of age.",[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),d,1 and 2,163625,DB00842,Oxazepam
up to,362051,half-life (T1/2(beta)),"While the normal half-life (T1/2(beta)) varies between 1 and 2 days, it can be increased to up to 80--100 h in subjects over 60 years of age.",[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),h,80--100,163626,DB00842,Oxazepam
,362051,hepatic clearance,"In patients with liver disease T1/2(beta) is about doubled, which is caused by a reduction (factor 2) of the normal hepatic clearance of 26 ml/min.",[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),[ml] / [min],26,163627,DB00842,Oxazepam
,362051,T1/2(beta),The major metabolite desmethyldiazepam has a T1/2(beta) of 51 h and a Cl of 11 ml/min and accumulates after multiple doses of diazepam since its elimination is much slower than that of its parent compound.,[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),h,51,163628,DB00842,Oxazepam
,362051,Cl,The major metabolite desmethyldiazepam has a T1/2(beta) of 51 h and a Cl of 11 ml/min and accumulates after multiple doses of diazepam since its elimination is much slower than that of its parent compound.,[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),[ml] / [min],11,163629,DB00842,Oxazepam
,362051,T1/2(beta),In contrast to these findings oxazepam is excreted as glucuronide in the urine relatively fast and independently of the liver function with a T1/2(beta) of 5.5 h and a Cl of 130 ml/min.,[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),h,5.5,163630,DB00842,Oxazepam
,362051,Cl,In contrast to these findings oxazepam is excreted as glucuronide in the urine relatively fast and independently of the liver function with a T1/2(beta) of 5.5 h and a Cl of 130 ml/min.,[Clinical pharmacokinetics of diazepam and its biologically active metabolites (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/362051/),[ml] / [min],130,163631,DB00842,Oxazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.2,165364,DB00842,Oxazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.13,165365,DB00842,Oxazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.14,165366,DB00842,Oxazepam
,2105100,milk: plasma ratios,"Diazepam, N-desmethyldiazepam, temazepam and oxazepam were found in the maternal plasma and milk with mean milk: plasma ratios of 0.2, 0.13, 0.14 and 0.10 respectively.",Excretion of diazepam and its metabolites in human milk during withdrawal from combination high dose diazepam and oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2105100/),,0.10,165367,DB00842,Oxazepam
,300541,Plasma clearance,Plasma clearance ranged between 0.050 and 0.171 x kg-1 x h-1 and half-lives from 5.9 to 25 hours.,Pharmacokinetics of oxazepam in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/300541/),1/[h·kg],0.050 and 0.171,165429,DB00842,Oxazepam
,300541,half-lives,Plasma clearance ranged between 0.050 and 0.171 x kg-1 x h-1 and half-lives from 5.9 to 25 hours.,Pharmacokinetics of oxazepam in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/300541/),h,5.9 to 25,165430,DB00842,Oxazepam
,300541,urinary recovery,The urinary recovery of oxazepam conjugates was 67 +/- 15 S.D.% of the dose given and the total recovery including faecal oxazepam was 70 +/- 15 S.D. %.,Pharmacokinetics of oxazepam in healthy volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/300541/),%,67,165431,DB00842,Oxazepam
,300541,total recovery,The urinary recovery of oxazepam conjugates was 67 +/- 15 S.D.% of the dose given and the total recovery including faecal oxazepam was 70 +/- 15 S.D. %.,Pharmacokinetics of oxazepam in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/300541/),%,70,165432,DB00842,Oxazepam
,3197746,elimination half-life (t1/2 beta),"The kinetic variables of i.v. oxazepam were: elimination half-life (t1/2 beta) 6.7 h, total clearance (CL) 1.07 ml.min-1.kg-1, volume of distribution (Vc) 0.27 l.kg-1 (0.21-0.49) and volume of distribution at steady-state (Vss) 0.59 l.kg-1.",Bioavailability and pharmacokinetics of oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),h,6.7,166412,DB00842,Oxazepam
,3197746,total clearance (CL),"The kinetic variables of i.v. oxazepam were: elimination half-life (t1/2 beta) 6.7 h, total clearance (CL) 1.07 ml.min-1.kg-1, volume of distribution (Vc) 0.27 l.kg-1 (0.21-0.49) and volume of distribution at steady-state (Vss) 0.59 l.kg-1.",Bioavailability and pharmacokinetics of oxazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),[ml] / [kg·min],1.07,166413,DB00842,Oxazepam
,3197746,volume of distribution (Vc),"The kinetic variables of i.v. oxazepam were: elimination half-life (t1/2 beta) 6.7 h, total clearance (CL) 1.07 ml.min-1.kg-1, volume of distribution (Vc) 0.27 l.kg-1 (0.21-0.49) and volume of distribution at steady-state (Vss) 0.59 l.kg-1.",Bioavailability and pharmacokinetics of oxazepam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),[l] / [kg],0.27,166414,DB00842,Oxazepam
,3197746,volume of distribution at steady-state (Vss),"The kinetic variables of i.v. oxazepam were: elimination half-life (t1/2 beta) 6.7 h, total clearance (CL) 1.07 ml.min-1.kg-1, volume of distribution (Vc) 0.27 l.kg-1 (0.21-0.49) and volume of distribution at steady-state (Vss) 0.59 l.kg-1.",Bioavailability and pharmacokinetics of oxazepam. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),[l] / [kg],0.59,166415,DB00842,Oxazepam
,3197746,clearance,The intravenous disposition of unbound oxazepam was characterized by a clearance of 22.5 ml.min-1.kg-1 and a distribution volume of 12.3 l.kg-1.,Bioavailability and pharmacokinetics of oxazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),[ml] / [kg·min],22.5,166416,DB00842,Oxazepam
,3197746,distribution volume,The intravenous disposition of unbound oxazepam was characterized by a clearance of 22.5 ml.min-1.kg-1 and a distribution volume of 12.3 l.kg-1.,Bioavailability and pharmacokinetics of oxazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),[l] / [kg],12.3,166417,DB00842,Oxazepam
,3197746,bioavailability,"Absorption was almost complete, with a bioavailability of 92.8%.",Bioavailability and pharmacokinetics of oxazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),%,92.8,166418,DB00842,Oxazepam
,3197746,Urinary recovery,"Urinary recovery was 80.0 and 71.4% of the dose after intravenous and oral administration, respectively.",Bioavailability and pharmacokinetics of oxazepam. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),%,80.0,166419,DB00842,Oxazepam
,3197746,Urinary recovery,"Urinary recovery was 80.0 and 71.4% of the dose after intravenous and oral administration, respectively.",Bioavailability and pharmacokinetics of oxazepam. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),%,71.4,166420,DB00842,Oxazepam
,3197746,Renal clearance (CLR),Renal clearance (CLR) of the glucuronide metabolite was 1.10 ml.min-1.kg-1 (0.98-1.52).,Bioavailability and pharmacokinetics of oxazepam. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),[ml] / [kg·min],1.10,166421,DB00842,Oxazepam
,3197746,free fraction,Oxazepam was extensively bound to plasma protein with a free fraction of 4.5%.,Bioavailability and pharmacokinetics of oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3197746/),%,4.5,166422,DB00842,Oxazepam
,8417175,bioavailability,The calculated bioavailability was 0.61 for zidovudine alone and 0.75 when administered in combination with oxazepam (p = 0.16).,Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),,0.61,170391,DB00842,Oxazepam
,8417175,bioavailability,The calculated bioavailability was 0.61 for zidovudine alone and 0.75 when administered in combination with oxazepam (p = 0.16).,Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),,0.75,170392,DB00842,Oxazepam
,8417175,Plasma half-life,"Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous zidovudine during single and combination therapy, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,1.17,170393,DB00842,Oxazepam
,8417175,Plasma half-life,"Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous zidovudine during single and combination therapy, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,0.99,170394,DB00842,Oxazepam
,8417175,Plasma half-life,"Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous zidovudine during single and combination therapy, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,1.38,170395,DB00842,Oxazepam
,8417175,Plasma half-life,"Plasma half-life for oral zidovudine alone and in combination with oxazepam was 1.17 h versus 0.99 h, respectively (p = 0.25), and 1.38 h versus 1.15 h (p = 0.38) for intravenous zidovudine during single and combination therapy, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,1.15,170396,DB00842,Oxazepam
,8417175,Total body clearance,"Total body clearance of zidovudine was not significantly altered by oxazepam (93 L/h vs. 109 L/h, p = 0.16).",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),[l] / [h],93,170397,DB00842,Oxazepam
,8417175,Total body clearance,"Total body clearance of zidovudine was not significantly altered by oxazepam (93 L/h vs. 109 L/h, p = 0.16).",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),[l] / [h],109,170398,DB00842,Oxazepam
,8417175,oral clearance,"The mean pharmacokinetic parameters determined for a single 30-mg dose of oxazepam for oral clearance, apparent volume of distribution, and plasma half-life were 9.8 L/h, 65.7 L, and 5.1 h, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),[l] / [h],9.8,170399,DB00842,Oxazepam
,8417175,apparent volume of distribution,"The mean pharmacokinetic parameters determined for a single 30-mg dose of oxazepam for oral clearance, apparent volume of distribution, and plasma half-life were 9.8 L/h, 65.7 L, and 5.1 h, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),l,65.7,170400,DB00842,Oxazepam
,8417175,plasma half-life,"The mean pharmacokinetic parameters determined for a single 30-mg dose of oxazepam for oral clearance, apparent volume of distribution, and plasma half-life were 9.8 L/h, 65.7 L, and 5.1 h, respectively.",Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8417175/),h,5.1,170401,DB00842,Oxazepam
,282777,half lives,In normal man half lives between 6 and 25 hours are obtained.,The pharmacokinetic profile of oxazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/282777/),h,6 and 25,174850,DB00842,Oxazepam
,282777,terminal half life,In uremic patients the terminal half life of oxazepam in plasma was prolonged to 24-91 hours.,The pharmacokinetic profile of oxazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/282777/),h,24-91,174851,DB00842,Oxazepam
,8701740,retention time,"The retention time for N-demethyldiazepam, oxazepam and internal standard were 4.85 min, 2.8 min and 8.5 min, respectively.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),min,4.85,177228,DB00842,Oxazepam
,8701740,retention time,"The retention time for N-demethyldiazepam, oxazepam and internal standard were 4.85 min, 2.8 min and 8.5 min, respectively.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),min,2.8,177229,DB00842,Oxazepam
,8701740,retention time,"The retention time for N-demethyldiazepam, oxazepam and internal standard were 4.85 min, 2.8 min and 8.5 min, respectively.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),min,8.5,177230,DB00842,Oxazepam
,8701740,lower detection limits,The lower detection limits for oxazepam and N-demethyldiazepam were 10 ng.,[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),ng,10,177231,DB00842,Oxazepam
,8701740,Tmax,"Its main pharmacokinetic parameters were: Tmax = 0.24 h, Cmax = 1211.78 ng.ml-1, T1/2 beta = 2.84 h, AUC = 1264 ng.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),h,0.24,177232,DB00842,Oxazepam
,8701740,Cmax,"Its main pharmacokinetic parameters were: Tmax = 0.24 h, Cmax = 1211.78 ng.ml-1, T1/2 beta = 2.84 h, AUC = 1264 ng.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),[ng] / [ml],1211.78,177233,DB00842,Oxazepam
,8701740,T1/2 beta,"Its main pharmacokinetic parameters were: Tmax = 0.24 h, Cmax = 1211.78 ng.ml-1, T1/2 beta = 2.84 h, AUC = 1264 ng.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),h,2.84,177234,DB00842,Oxazepam
,8701740,AUC,"Its main pharmacokinetic parameters were: Tmax = 0.24 h, Cmax = 1211.78 ng.ml-1, T1/2 beta = 2.84 h, AUC = 1264 ng.",[Determination of N-demethyldiazepam and its metabolite oxazepam in plasma by HPLC and their pharmacokinetics in rats]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8701740/),ng,1264,177235,DB00842,Oxazepam
,8599525,systemic availability,"Mean (+/- SD) diazepam concentrations in plasma after rectal administration were low in comparison with those obtained after IV administration, with systemic availability of only 7.4 (+/- 5.9) and 2.7 (+/- 3.2)% for the high and low dose, respectively.",Absorption of diazepam after its rectal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),%,7.4,186530,DB00842,Oxazepam
,8599525,systemic availability,"Mean (+/- SD) diazepam concentrations in plasma after rectal administration were low in comparison with those obtained after IV administration, with systemic availability of only 7.4 (+/- 5.9) and 2.7 (+/- 3.2)% for the high and low dose, respectively.",Absorption of diazepam after its rectal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),%,2.7,186531,DB00842,Oxazepam
,8599525,systemic availability,"Accounting for the total concentration of benzodiazepines (diazepam plus desmethyldiazepam and oxazepam) in plasma, systemic availability was 79.9 (+/- 20.7) and 66.0 (+/- 23.8)% for the high and low dosage, respectively.",Absorption of diazepam after its rectal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),%,79.9,186532,DB00842,Oxazepam
,8599525,systemic availability,"Accounting for the total concentration of benzodiazepines (diazepam plus desmethyldiazepam and oxazepam) in plasma, systemic availability was 79.9 (+/- 20.7) and 66.0 (+/- 23.8)% for the high and low dosage, respectively.",Absorption of diazepam after its rectal administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),%,66.0,186533,DB00842,Oxazepam
,8599525,half-life,"After IV administration, diazepam concentration decreased, with a half-life of only 14 to 16 minutes, but desmethyldiazepam and oxazepam concentrations decreased more slowly, with a half-life of 2.2 to 2.8 hours and 3.5 to 5.1 hours, respectively.",Absorption of diazepam after its rectal administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),min,14 to 16,186534,DB00842,Oxazepam
,8599525,half-life,"After IV administration, diazepam concentration decreased, with a half-life of only 14 to 16 minutes, but desmethyldiazepam and oxazepam concentrations decreased more slowly, with a half-life of 2.2 to 2.8 hours and 3.5 to 5.1 hours, respectively.",Absorption of diazepam after its rectal administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),h,2.2 to 2.8,186535,DB00842,Oxazepam
,8599525,half-life,"After IV administration, diazepam concentration decreased, with a half-life of only 14 to 16 minutes, but desmethyldiazepam and oxazepam concentrations decreased more slowly, with a half-life of 2.2 to 2.8 hours and 3.5 to 5.1 hours, respectively.",Absorption of diazepam after its rectal administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8599525/),h,3.5 to 5.1,186536,DB00842,Oxazepam
,2873990,Vmax,"Ciramadol glucuronidation was slower (Vmax, 1.56 vs. 5.40 nmol/min/mg of microsomal protein) in human than in dog liver microsomes.",Inhibition of ciramadol glucuronidation by benzodiazepines. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873990/),[nM] / [mg·min],1.56,187947,DB00842,Oxazepam
,2873990,Vmax,"Ciramadol glucuronidation was slower (Vmax, 1.56 vs. 5.40 nmol/min/mg of microsomal protein) in human than in dog liver microsomes.",Inhibition of ciramadol glucuronidation by benzodiazepines. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873990/),[nM] / [mg·min],5.40,187948,DB00842,Oxazepam
,25531873,matrix effect,The matrix effect of normal and hemolyzed plasma was 94.9-101.6%.,Rapid determination of fenoldopam in human plasma by UPLC-MS/MS for pharmacokinetic analysis in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25531873/),%,94.9-101.6,188252,DB00842,Oxazepam
,10316,Recoveries,"Recoveries of 97-98% have been obtained and the trifluoroacetic (TFA) derivatives of both benzophenones (ACB-TFA and ACDB-TFA) can be chromatographed on OV-17, in a short time, with good electron-capture detector (ECD) responses.",Electron capture and multiple ion detection of benzodiazepine esters in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10316/),%,97-98,188758,DB00842,Oxazepam
,10316,detection limits,The detection limits in blood specimens have been established at 5-10 ng/ml by ECD and 0.5-0.8 ng/ml by MID.,Electron capture and multiple ion detection of benzodiazepine esters in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10316/),[ng] / [ml],5-10,188759,DB00842,Oxazepam
,10316,detection limits,The detection limits in blood specimens have been established at 5-10 ng/ml by ECD and 0.5-0.8 ng/ml by MID.,Electron capture and multiple ion detection of benzodiazepine esters in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10316/),[ng] / [ml],0.5-0.8,188760,DB00842,Oxazepam
,11470209,analytical run time,The analytical run time was 5 min.,The simultaneous determination of diazepam and its three metabolites in dog plasma by high-performance liquid chromatography with mass spectroscopy detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11470209/),min,5,194420,DB00842,Oxazepam
,1867967,total oxazepam clearance,"The total oxazepam clearance was 1.24 (0.91-1.80) ml min-1 kg-1 (median and range) and 1.44 (0.88-2.13) ml min-1 kg-1 in the elderly and young, respectively (NS), and the elimination half-lives were 8.1 (5.5-10.8) h and 5.7 (4.9-6.2) h. respectively (P less than 0.01).",Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867967/),[ml] / [kg·min],1.24,197582,DB00842,Oxazepam
,1867967,total oxazepam clearance,"The total oxazepam clearance was 1.24 (0.91-1.80) ml min-1 kg-1 (median and range) and 1.44 (0.88-2.13) ml min-1 kg-1 in the elderly and young, respectively (NS), and the elimination half-lives were 8.1 (5.5-10.8) h and 5.7 (4.9-6.2) h. respectively (P less than 0.01).",Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867967/),[ml] / [kg·min],1.44,197583,DB00842,Oxazepam
,1867967,elimination half-lives,"The total oxazepam clearance was 1.24 (0.91-1.80) ml min-1 kg-1 (median and range) and 1.44 (0.88-2.13) ml min-1 kg-1 in the elderly and young, respectively (NS), and the elimination half-lives were 8.1 (5.5-10.8) h and 5.7 (4.9-6.2) h. respectively (P less than 0.01).",Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867967/),h,8.1,197584,DB00842,Oxazepam
,1867967,elimination half-lives,"The total oxazepam clearance was 1.24 (0.91-1.80) ml min-1 kg-1 (median and range) and 1.44 (0.88-2.13) ml min-1 kg-1 in the elderly and young, respectively (NS), and the elimination half-lives were 8.1 (5.5-10.8) h and 5.7 (4.9-6.2) h. respectively (P less than 0.01).",Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867967/),h,5.7,197585,DB00842,Oxazepam
,1867967,Clearance of unbound oxa,"Clearance of unbound oxazepam was lower in the elderly, median values being 13.8 (7.1-21.1) ml min-1 kg-1 compared with 30.3 (18.3-41.5) ml min-1 kg-1 in the young (P less than 0.0001).",Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867967/),[ml] / [kg·min],13.8,197586,DB00842,Oxazepam
,1867967,Clearance of unbound oxa,"Clearance of unbound oxazepam was lower in the elderly, median values being 13.8 (7.1-21.1) ml min-1 kg-1 compared with 30.3 (18.3-41.5) ml min-1 kg-1 in the young (P less than 0.0001).",Single dose pharmacokinetics and pharmacodynamics of oral oxazepam in very elderly institutionalised subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867967/),[ml] / [kg·min],30.3,197587,DB00842,Oxazepam
,1572756,area under the plasma concentration-time curve,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[h·ng] / [ml],"4,910",201527,DB00842,Oxazepam
,1572756,area under the plasma concentration-time curve,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[h·ng] / [ml],"5,581",201528,DB00842,Oxazepam
,1572756,peak concentrations,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[ng] / [ml],40,201529,DB00842,Oxazepam
,1572756,peak concentrations,"However, the co-administration of felodipine increased desmethyldiazepam plasma concentrations relative to placebo: mean area under the plasma concentration-time curve of 4,910 vs 5,581 ng.h/ml and mean peak concentrations of 40 vs 47 ng/ml.",The effects of felodipine on the pharmacokinetics of diazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572756/),[ng] / [ml],47,201530,DB00842,Oxazepam
,3418496,half-lives of distribution,"After determination of the pharmacokinetics of oxazepam, which could be described with a two-compartment model (half-lives of distribution and elimination 6 and 52 min, respectively), the drug was administered iv to groups of animals to achieve a serum concentration range of 0.1-2.5 mg/L at 10, 45, and 120 min after administration.",Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418496/),min,6,210900,DB00842,Oxazepam
,3418496,half-lives of distribution,"After determination of the pharmacokinetics of oxazepam, which could be described with a two-compartment model (half-lives of distribution and elimination 6 and 52 min, respectively), the drug was administered iv to groups of animals to achieve a serum concentration range of 0.1-2.5 mg/L at 10, 45, and 120 min after administration.",Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418496/),min,52,210901,DB00842,Oxazepam
,3418496,elimination,"After determination of the pharmacokinetics of oxazepam, which could be described with a two-compartment model (half-lives of distribution and elimination 6 and 52 min, respectively), the drug was administered iv to groups of animals to achieve a serum concentration range of 0.1-2.5 mg/L at 10, 45, and 120 min after administration.",Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418496/),min,6,210902,DB00842,Oxazepam
,3418496,elimination,"After determination of the pharmacokinetics of oxazepam, which could be described with a two-compartment model (half-lives of distribution and elimination 6 and 52 min, respectively), the drug was administered iv to groups of animals to achieve a serum concentration range of 0.1-2.5 mg/L at 10, 45, and 120 min after administration.",Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418496/),min,52,210903,DB00842,Oxazepam
,3418496,EC50,"The total serum and brain oxazepam EC50 values are about 0.5 mg/L and 1.1 mg/kg, respectively, and Emax 120 mg/L PTZ.",Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418496/),[mg] / [kg],1.1,210904,DB00842,Oxazepam
,3418496,Emax,"The total serum and brain oxazepam EC50 values are about 0.5 mg/L and 1.1 mg/kg, respectively, and Emax 120 mg/L PTZ.",Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3418496/),[mg] / [l],120,210905,DB00842,Oxazepam
,7981015,AUC,The mean (+/- s.d.) AUC (ng ml-1h-1) of oxazepam over 24 h during combined treatment was 4716 +/- 2296 and for oxazepam treatment alone it was 4737 +/- 2448 (95% confidence intervals for ratio of means = 95.4-103.7%).,Lack of pharmacokinetic interaction between vinpocetine and oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981015/),[ng] / [ml],4716,214596,DB00842,Oxazepam
,7981015,AUC,The mean (+/- s.d.) AUC (ng ml-1h-1) of oxazepam over 24 h during combined treatment was 4716 +/- 2296 and for oxazepam treatment alone it was 4737 +/- 2448 (95% confidence intervals for ratio of means = 95.4-103.7%).,Lack of pharmacokinetic interaction between vinpocetine and oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981015/),[ng] / [ml],4737,214597,DB00842,Oxazepam
,7981015,plasma protein binding,The degree of plasma protein binding of oxazepam was 98.11 +/- 0.32% and was not affected by vinpocetine.,Lack of pharmacokinetic interaction between vinpocetine and oxazepam. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981015/),%,98.11,214598,DB00842,Oxazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,4.9,216455,DB00842,Oxazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,9.2,216456,DB00842,Oxazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,1.0,216457,DB00842,Oxazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,6.2,216458,DB00842,Oxazepam
,21692812,terminal half-life,"The terminal half-life was 4.9, 9.2, and 1.0 h, respectively, for phenytoin, theophylline, and diazepam, and 6.2 and 2.4 h for oxazepam and nordiazepam after IV diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),h,2.4,216459,DB00842,Oxazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],2.37,216460,DB00842,Oxazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],0.935,216461,DB00842,Oxazepam
,21692812,clearance,"The clearance was of 2.37, 0.935, and 27.9 mL · min/kg, respectively, for phenytoin, theophylline, and diazepam.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[min·ml] / [kg],27.9,216462,DB00842,Oxazepam
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],44.7,216463,DB00842,Oxazepam
,21692812,C(MAX),"The C(MAX) was 44.7 and 305.2 ng/mL for oxazepam and nordiazepam, respectively, after diazepam administration.","Pharmacokinetics of the cytochrome P-450 substrates phenytoin, theophylline, and diazepam in healthy Greyhound dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21692812/),[ng] / [ml],305.2,216464,DB00842,Oxazepam
,12742689,ICRs,The ICRs ranged from 0.002 (flunitrazepam) to 0.049 (flurazepam).,A study into the rate of incorporation of eight benzodiazepines into rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742689/),,0.002,222417,DB00842,Oxazepam
,12742689,ICRs,The ICRs ranged from 0.002 (flunitrazepam) to 0.049 (flurazepam).,A study into the rate of incorporation of eight benzodiazepines into rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742689/),,0.049,222418,DB00842,Oxazepam
,2207300,peak plasma level (Cmax),"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),[ng] / [ml],873,225970,DB00842,Oxazepam
,2207300,time of peak,"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),h,1.36,225971,DB00842,Oxazepam
,2207300,volume of distribution,"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),1/[kg],0.961,225972,DB00842,Oxazepam
,2207300,elimination half-life,"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),h,9.9,225973,DB00842,Oxazepam
,2207300,clearance,"Mean kinetic variables for temazepam in plasma were: peak plasma level (Cmax), 873 ng ml-1; time of peak, 1.36 h after dosage; volume of distribution, 0.961 kg-1; elimination half-life 9.9 h; clearance, 1.16 ml min-1 kg-1.",Oxidative versus conjugative biotransformation of temazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2207300/),[ml] / [kg·min],1.16,225974,DB00842,Oxazepam
,6685514,relative bioavailability,As compared to the reference preparation the relative bioavailability of the test preparation as 110%; both preparations are therefore bioequivalent.,[Comparative test of the bioavailability and pharmacokinetics of 2 oxazepam preparations using high-pressure liquid chromatography]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685514/),%,110,226820,DB00842,Oxazepam
,2908106,ED50,"The ED50 of the drug was 12 mg/kg at 1 min against pentetrazole-induced convulsions (45 mg/kg i.v.), it reached a minimum at 1 h (2.0 mg/kg) and rose to 2.7 mg/kg at 2 h.","Clorazepate, correlation between metabolism and anticonvulsant activity. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908106/),[mg] / [kg],12,239133,DB00842,Oxazepam
,2908106,ED50,"The ED50 of the drug was 12 mg/kg at 1 min against pentetrazole-induced convulsions (45 mg/kg i.v.), it reached a minimum at 1 h (2.0 mg/kg) and rose to 2.7 mg/kg at 2 h.","Clorazepate, correlation between metabolism and anticonvulsant activity. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908106/),[mg] / [kg],2.7,239134,DB00842,Oxazepam
,8563769,S/R ratios,"The ratios of (S) to (R) glucuronide metabolites (S/R ratios) were 3.87 +/- 0.79 (mean +/- SD) and 3.52 +/- 0.60 in urine and plasma, respectively.",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),,3.87,246143,DB00842,Oxazepam
,8563769,S/R ratios,"The ratios of (S) to (R) glucuronide metabolites (S/R ratios) were 3.87 +/- 0.79 (mean +/- SD) and 3.52 +/- 0.60 in urine and plasma, respectively.",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),,3.52,246144,DB00842,Oxazepam
,8563769,half-life,"In these two atypical subjects, the half-life of (R,S) oxazepam was also markedly longer (14.7 and 15.9 h) than in the other subjects (8.1 +/- 3.2 h).",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),h,14.7,246145,DB00842,Oxazepam
,8563769,half-life,"In these two atypical subjects, the half-life of (R,S) oxazepam was also markedly longer (14.7 and 15.9 h) than in the other subjects (8.1 +/- 3.2 h).",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),h,15.9,246146,DB00842,Oxazepam
,8563769,half-life,"In these two atypical subjects, the half-life of (R,S) oxazepam was also markedly longer (14.7 and 15.9 h) than in the other subjects (8.1 +/- 3.2 h).",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),h,8.1,246147,DB00842,Oxazepam
,8563769,apparent antimode,"The S/R-glucuronide ratio in 8 h pooled urine was bimodally distributed, with 10% of all subjects possessing ratios below an apparent antimode of 1.9.",Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563769/),,1.9,246148,DB00842,Oxazepam
,2331575,clearance,"Following 12 mg kg-1 the values (mean +/- s.e., n = 11) of clearance and volume of distribution were 28 +/- 2 ml min-1 kg-1 and 2.6 +/- 0.31 kg-1, respectively, and were not significantly different from the values obtained at the other doses.",Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331575/),[ml] / [kg·min],28,248333,DB00842,Oxazepam
,2331575,volume of distribution,"Following 12 mg kg-1 the values (mean +/- s.e., n = 11) of clearance and volume of distribution were 28 +/- 2 ml min-1 kg-1 and 2.6 +/- 0.31 kg-1, respectively, and were not significantly different from the values obtained at the other doses.",Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331575/),1/[kg],2.6,248334,DB00842,Oxazepam
,2331575,slope,"Following 12 mg kg-1 the values (mean +/- s.e., n = 11) of the pharmacodynamic parameters slope and minimal effective concentration (Cmin) were 243 +/- 27 microA and 0.11 +/- 0.02 mg l-1, respectively and not significantly different from the values obtained at the other doses.",Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331575/),μa,243,248335,DB00842,Oxazepam
,2331575,minimal effective concentration (Cmin),"Following 12 mg kg-1 the values (mean +/- s.e., n = 11) of the pharmacodynamic parameters slope and minimal effective concentration (Cmin) were 243 +/- 27 microA and 0.11 +/- 0.02 mg l-1, respectively and not significantly different from the values obtained at the other doses.",Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331575/),[mg] / [l],0.11,248336,DB00842,Oxazepam
,2331575,minimal effective concentration,The value of the minimal effective concentration was in each animal and on each occasion close to zero within the relatively narrow range of 0.01-0.30mgI.,Pharmacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331575/),,0.01-0.30,248337,DB00842,Oxazepam
,1870948,plasma ratio R/S-,The plasma ratio R/S-glucuronide is 1:1 for both oxazepam and temazepam.,Direct high pressure liquid chromatographic analysis and preliminary pharmacokinetics of enantiomers of oxazepam and temazepam with their corresponding glucuronide conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1870948/),,1:,250404,DB00842,Oxazepam
,1870948,plasma ratio R/S-,The plasma ratio R/S-glucuronide is 1:1 for both oxazepam and temazepam.,Direct high pressure liquid chromatographic analysis and preliminary pharmacokinetics of enantiomers of oxazepam and temazepam with their corresponding glucuronide conjugates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1870948/),,1,250405,DB00842,Oxazepam
,7149375,Total body clearances,"Total body clearances of diazepam were between 6.94 and 9.56 ml/min/kg, and the half-life values between 2.52 and 21.6 hours.",Pharmacodynamic and pharmacokinetic properties of diazepam in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149375/),[ml] / [kg·min],6.94 and 9.56,253633,DB00842,Oxazepam
,7149375,half-life,"Total body clearances of diazepam were between 6.94 and 9.56 ml/min/kg, and the half-life values between 2.52 and 21.6 hours.",Pharmacodynamic and pharmacokinetic properties of diazepam in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149375/),h,2.52 and 21.6,253634,DB00842,Oxazepam
,7149375,volume of distribution at steady state,The volume of distribution at steady state was 1.56 to 2.94 L/kg.,Pharmacodynamic and pharmacokinetic properties of diazepam in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7149375/),[l] / [kg],1.56 to 2.94,253635,DB00842,Oxazepam
,359214,elimination half-life (tl/2beta),"The elimination half-life (tl/2beta) of chlordiazepoxide following single doses, in healthy individuals generally ranges from 5 to 30 hours, and the volume of distribution from 0.25 to 0.50 liters/kg.",Clinical pharmacokinetics of chlordiazepoxide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/359214/),h,5 to 30,254720,DB00842,Oxazepam
,359214,volume of distribution,"The elimination half-life (tl/2beta) of chlordiazepoxide following single doses, in healthy individuals generally ranges from 5 to 30 hours, and the volume of distribution from 0.25 to 0.50 liters/kg.",Clinical pharmacokinetics of chlordiazepoxide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/359214/),[l] / [kg],0.25 to 0.50,254721,DB00842,Oxazepam
under,359214,hepatic extraction ratio,The hepatic extraction ratio is well under 5%.,Clinical pharmacokinetics of chlordiazepoxide. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/359214/),%,5,254722,DB00842,Oxazepam
,2872062,elimination half-life,"The mean elimination half-life in the control subjects was 15.5 h, considerably longer than previous estimates.",The effects of age and chronic liver disease on the elimination of temazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872062/),h,15.5,260040,DB00842,Oxazepam
more,8704938,Extraction recovery,Extraction recovery from serum proved to be more than 86%.,Simple high-performance liquid chromatographic separation of oxazepam and its diastereoisomeric glucuronides in serum. Applications in a pharmacokinetic study in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8704938/),%,86,264657,DB00842,Oxazepam
,3239381,penetration,"The penetration of diazepam and oxazepam from maternal serum to placental tissue in a 4 h period after drug administration was 31.5% and 49%, respectively, indicating a rapid transfer.",Pharmacokinetics and distribution of diazepam and oxazepam in early pregnancy. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239381/),%,31.5,264711,DB00842,Oxazepam
,3239381,penetration,"The penetration of diazepam and oxazepam from maternal serum to placental tissue in a 4 h period after drug administration was 31.5% and 49%, respectively, indicating a rapid transfer.",Pharmacokinetics and distribution of diazepam and oxazepam in early pregnancy. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3239381/),%,49,264712,DB00842,Oxazepam
,2108448,elimination half life,Oxazepam is eliminated with a relatively short elimination half life (ca. 150 min) in both acutely and chronically treated dogs.,The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108448/),min,150,266373,DB00842,Oxazepam
,2108448,first pass metabolism,It exhibits only a modest first pass metabolism (ca. 10%) and its bioavailability following oral administration is about 22%.,The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108448/),%,10,266374,DB00842,Oxazepam
,2108448,bioavailability,It exhibits only a modest first pass metabolism (ca. 10%) and its bioavailability following oral administration is about 22%.,The effects of flumazenil-precipitated abstinence on the pharmacokinetics of chronic oxazepam in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2108448/),%,22,266375,DB00842,Oxazepam
,9091281,Elimination half-life (t1/2 beta),Elimination half-life (t1/2 beta) after a dose of 0.05-0.08 mg/kg (30-50 mg Diazepam per horse) was 7.5 to 13.2 h.,[Kinetics of elimination of diazepam after intravenous injection in horses]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091281/),h,7.5 to 13.2,274223,DB00842,Oxazepam
,9091281,Total clearance (Cltot),Total clearance (Cltot) between 1.86 and 3.44 ml/min/kg was detected and apparent volume of distribution in steady state (Vdiss) was 1.98 to 2.25 l/kg.,[Kinetics of elimination of diazepam after intravenous injection in horses]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091281/),[ml] / [kg·min],1.86 and 3.44,274224,DB00842,Oxazepam
,9091281,apparent volume of distribution in steady state (Vdiss),Total clearance (Cltot) between 1.86 and 3.44 ml/min/kg was detected and apparent volume of distribution in steady state (Vdiss) was 1.98 to 2.25 l/kg.,[Kinetics of elimination of diazepam after intravenous injection in horses]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091281/),[l] / [kg],1.98 to 2.25,274225,DB00842,Oxazepam
,9091281,elimination half-life,Its elimination half-life was 14-16.5 hours.,[Kinetics of elimination of diazepam after intravenous injection in horses]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9091281/),h,14-16.5,274226,DB00842,Oxazepam
